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Introduction
Non-Hodgkin lymphomas (NHLs) occur as a result of an expansion and progressive 
accumulation of a mature single clone of lymphocytes(1). The most common subtype, diffuse 
large B-Cell lymphoma (DLBCL), is characterized by a diffuse proliferation of large and 
mature B-cells. These cells usually are larger than, or equal to, twice the normal size of 
macrophages or lymphocytes(2).
DLBCL is clinically and biologically heterogeneous, aggressive, and includes several 
subtypes(2). It may arise as primary or de novo, or may result from a transformation of an 
indolent lymphoma(3). The majority of cases occur in lymph nodes with 40% in extranodal 
sites(4). These cases occur most frequently in the gastrointestinal tract, but may appear in any 
organ, including the skin, central nervous system (CNS), bone marrow (BM), salivary gland, 
lung, kidney, and liver(5,6). Bone marrow involvement is found in 11% to 27% of all cases but 
rarely infiltrates the peripheral blood(7).
Initially, the classification of NHL was based on morphological features of the malignant 
cell, but today it is also based on immunological and molecular data. Thus, complementary 
techniques of immunohistochemistry, flow cytometry, cytogenetic, polymerase chain reaction, 
and gene signature by microarray are used.
According to the World Health Organization (WHO)(7), DLBCLs may be subdivided into 
morphological variants.
The centroblastic variant presents medium to large lymphoid cells, vesicular nuclei, fine 
chromatin and scant cytoplasm. In some cases, it may feature cells with multiple lobules and 
more than 90% of immunoblasts with a marked polymorphism. Shahi & Manga(3) observed 
one to three prominent basophilic nucleoli in some cases. Indeed, they suggest that this variant 
may present two morphological subtypes. The first is called the monomorphic subtype, with 
almost 100% of centroblasts, and the second, comprising of 10% of centroblasts and less than 
90% of immunoblasts, the polymorphic subtype(7).
In the immunoblast subtype, the cell population comprises more than 90% of 
immunoblasts. It is characterized by cells with a single central nucleus and a basophilic 
and variable cytoplasm, but less than 10% of centroblasts. Immunophenotyping and clinical 
characteristics are essential to differentiate it from the plasmablastic variant of DLBCL. 
According to Shahi & Manga(3), the plasmablastic variant represents 10% of all DLBCL and 
is more common in immunosuppressed patients, especially those with HIV(7).
Diffuse large B-Cell lymphoma is the most common subtype of non-Hodgkin lymphoma in the West. In 
Brazil, it is the fifth cause of cancer, with more than 55,000 cases and 26,000 deaths per year. At Hospital 
das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP, diffuse large B-Cell 
lymphoma represents 49.7% of all non-Hodgkin lymphoma cases. Initially, the classification of non-Hodgkin 
lymphoma was based on morphology, but advances in immunology and molecular medicine allowed the 
introduction of a biological classification for these diseases. As for other cancers, non-Hodgkin lymphoma 
involves patterns of multifactorial pathogenesis with environmental factors, as well as genetic, occupational 
and dietary factors, contributing to its development. Multiple lesions involving molecular pathways of 
B-cell proliferation and differentiation may result in the activation of oncogenes such as the BCL2, BCL6, 
and MYC genes and the inactivation of tumor suppressor genes such as p53 and INK4, as well as other 
important transcription factors such as OCT-1 and OCT-2. A dramatic improvement in survival was seen 
after the recent introduction of the anti-CD20 monoclonal antibody. The association of this antibody to the 
cyclophosphamide, hydroxydaunorubicin, oncovin and prednisolone (CHOP) regimen has increased overall 
survival of diffuse large B-Cell lymphoma and follicular lymphoma patients by 20%. However, 50% of all 
diffuse large B-Cell lymphoma patients remain incurable, creating a demand for more research with new 
advances in treatment. Thus, it is important to know and understand the key factors and molecular pathways 
involved in the pathogenesis of diffuse large B-Cell lymphoma.
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DLBCL rich in T-cells and histiocytes is formed by a high 
quantity of reactive T-cells with or without histiocytes, and less 
than 10% of large neoplastic B-cells. The growth pattern of this 
subtype of DLBCL is predominantly diffuse, with fine reticular 
fibers in the tumor microenvironment. Immunophenotyping 
is essential to differentiate it from classic Hodgkin lymphoma 
(cHL). This variant is rare and presents a worse prognosis(6).
The anaplastic subtype is characterized by oval or 
polygonal cells with pleomorphic nuclei. Cells may take on a 
cohesive growth pattern, such as that found in carcinoma, or 
a sinusoidal growth pattern. The malignant cells express the CD30 
(ki-1) antigen and the main differential diagnoses are Hodgkin’s 
lymphoma (HL) and T-cell NHL that express CD30(6).
Primary Central Nervous System (CNS) DLBCL represents 
all cases of intra-cerebral or intraocular lymphomas and 
corresponds to less than 1% of NHL cases and 2-3% of all brain 
tumors. The average age at incidence is 60 years. The clinical 
characteristics are neurological disorders as observed in 80% of 
patients. Neuropsychiatric symptoms are observed in 20 to 30% 
and high intracranial pressure may also be observed(7).
Primary cutaneous DLBCL (leg type) represents 4% of all 
primary cutaneous DLBCL, and 20% of all primary cutaneous 
B-cell lymphomas. It occurs in elderly women in the seventh 
decade of life. It usually affects the legs but in 10 to 15% may 
occur in other sites(7).
Epstein-Barr Virus (EBV)-positive DLBCL of the elderly 
is a clonal proliferation of large B-cells. Its incidence is more 
common after the fifth decade of life and in patients with no 
previous immunodeficiency. Other rare subtypes of DLBCL are 
lymphomatoid granulomatosis and primary effusion lymphoma. 
DLBCL associated with chronic inflammation is a lymphoid 
neoplasm associated with EBV. The mean time elapsed between 
chronic inflammation and lymphoma is 10 years. Diagnosis 
occurs between the fifth and eighth decades of life with a median 
age of 65 years. The most common sites of involvement are the 
pleural cavity, femur and periarticular tissue. The tumor mass is 
greater than 10 cm in more than half of all cases. There is direct 
invasion of adjacent structures, but the tumor is often limited to 
the thoracic cavity until diagnosis. About 70% of patients present 
clinical stage I or II(7).
Unclassifiable B-cell lymphomas with features 
intermediate between DLBCL and Burkitt Lymphoma (BL) 
are aggressive lymphomas that, owing to their clinical and 
biological characteristics, may not be included in one of these 
two categories. In most cases, morphological characteristics 
are intermediate, with cells smaller than in typical DLBCL and 
larger than in typical BL but the phenotype of cells is compatible 
with BL. This lymphoma is rare in adults and more than half 
the patients show extranodal disease, such as bone marrow and 
peripheral blood involvement(7).
B-cell lymphomas with features intermediate between 
DLBCL and cHL are common in young males (20 to 40 
years). Etiology is unknown and the most common site 
of involvement is the mediastinum, with or without the 
involvement of lymph nodes(7).
Studies of gene expression patterns divided DLBCL into 
three subtypes that are morphologically indistinguishable: 
activated B-cell DLBCL, germinal center DLBCL, and primary 
mediastinal B-cell lymphoma. They express distinct genes that 
have been found at different stages of B-cell differentiation(8).
Epidemiology
DLBCL represents 80% of all aggressive lymphomas(3) and 
30 to 40% of all NHL cases in the West and are one of the most 
frequent in developing countries(2). At the Hospital das Clínicas 
da Faculdade de Medicina da Universidade de São Paulo - 
HCFMUSP, DLBCL represents 49.57% of all NHL cases(9). 
NHL is the fifth most common type of cancer in Brazil, with an 
incidence of 55,000 cases and over 26,000 deaths per year(10). In 
São Paulo, in 1998, the incidence of NHL cases was 12.2/100 
thousand inhabitants(11). Likewise, DLBCL is the most common 
lymphoma in adults (31%), followed by follicular lymphoma (FL)
(12-14). The median age at incidence is 70 years and it predominates 
in males (55%)(12).
According to Friedberg (12), the incidence of DLBCL has 
been increasing by 3 to 4% per year in both genders, in white 
and non-white populations, and in all age groups, except 
for adolescents. Factors such as more sensitive diagnostic 
techniques, changes in the classification of lymphoproliferative 
disorders and, particularly, the increase of NHL in HIV patients 
have contributed to the escalation in the incidence of this disease.
Environmental factors, as well as genetic, occupational 
and dietary factors, may have contributed to the development 
of NHL(15). NHLs are associated with chronic inflammatory 
diseases such as Sjögren syndrome, celiac disease and 
rheumatoid arthritis. Indeed, infectious agents are also related to 
the pathogenesis, but no greater incidence of NHL has been found 
in individuals who handle organic solvents, organophosphates, 
benzene or carbon tetrachloride(16).
In DLBCL, factors such as ultraviolet radiation, pesticides, 
and hair dye are potentially associated with higher risk. In 
addition, immunosuppression, especially related to HIV, is a risk 
factor and it may be associated with Epstein-Barr virus(13).
Pathophysiology
DLBCL arises from mature B-cells at different stages of 
differentiation. Several gene mutations promote changes in 
B-cells, changing the gene expression and promoting a neoplastic 
transformation (Figure 1)(17).
During B lymphocyte ontogeny, after leaving the bone 
marrow, those cells travel to secondary lymphoid tissues 
where they will find their respective antigens promoting the 
development of secondary follicles. An antigen-dependent phase 
of B-cell development occurs at this site. In the germinal center 
of the secondary follicle, these lymphocytes are transformed 
into centroblasts that have a high rate of proliferation, while 
frequent and continuous somatic mutations of genes of the 
immunoglobulin variable chain occur, promoting maturation 
and differentiation into centrocytes and subsequently into 
plasma cells or in memory B-cells(17). In the germinal center, 
the BCL2 gene expression is usually down regulated and BCL6 
is hyperexpressed(8,17).
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Molecular Events Involved in DLBCL Pathogenesis
Proto-oncogenes are important to control cell proliferation. 
However, when inappropriately activated by genetic 
abnormalities such as chromosomal translocations, gene 
mutations or amplification, the cells may acquire a malignant 
transformation. In contrast, tumor suppressor genes promote cell 
differentiation and decreased cell proliferation. In the malignant 
transformation process, oncogene activation and inhibition of the 
tumor suppressor genes usually occur. Similar to other cancers, 
the pathogenesis of DLBCL occurs in multiple steps that results 
in the development of the disease (Figure 2)(1,14,18).
As previously described, the B lymphocyte ontogeny 
occurs in the bone marrow and in peripheral lymphoid tissues 
and depends on various genetic recombinations that function 
as points of vulnerability, subject to deleterious events that 
affect the immune system and the individual. However, in most 
cases, protective mechanisms surmount these disorders and the 
physiological homeostasis is preserved resulting in the formation 
of immunologically perfect B-cells. Examples of important 
genetic events that are essential in the development of B-cells are 
the recombination of genes encoding the heavy Ig chains driven 
by the RAG1 and RAG2 genes, and the hypermutation of variable 
regions of the genes responsible for encoding the light Ig chains 
and the switch of the Ig class(1,8).
The BCL6 gene is one of the most frequently affected in 
DLBCL. On the other hand, the t(14;18), which juxtaposes the 
BCL2 oncogene located on chromosome 18 to the promoter 
region of the gene encoding the heavy Ig chain on chromosome 
14, results in an overexpression of the BCL2 protein, a condition 
found in 15% to 30% of all DLBCL cases(14,19-22).
Main oncogenes involved in the pathogenesis of 
DLBCL 
BCL2
The BCL2 gene, which encodes an anti-apoptotic protein 
located in the outer membrane of the mitochondria and 
cytoplasm, plays an important role in the pathogenesis of NHL. 
This protein is involved in mechanisms related to resistance to 
chemotherapy(23-25). Amen et al.(26) demonstrated higher overall 
survival and disease-free survival in DLBCL with no BCL2 and 
Cyclin D2 expression. However, other authors have demonstrated 
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Figure 1 - Diagram of the differentiation and maturation of normal B lymphocytes and possible 
molecular alterations that can lead to the pathogenesis of diffuse large B-Cell lymphoma
Guilherme et al.(17) - adapted by the authors.
Figure 2 - Main genetic lesions that occur in the pathogenesis of diffuse 
large B-Cell lymphoma (DLBCL) and their respective frequencies.
Lossos(14) - adapted by the authors.
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a negative effect of the expression of BCL2 only in the subgroup 
of activated B-cell DLBCL(22-25,27).
BCL6 Gene
The BCL6 gene is a proto-oncogene located on chromosome 
3q27 expressed on normal B-cells in the germinal center(28-30). The 
BCL6 protein blocks genes involved in cell cycle progression 
and response to DNA damage(8). Chromosomal translocations 
involving the BCL6 gene occur in 30% to 40% of tumors and arise 
from disorders in the sequence in the promoter region of DNA. The 
role of the BCL6 gene in the pathogenesis of DLBCL was recently 
elucidated. Alterations in BCL6 protein expression may cause 
failure in cell differentiation and continuous activation and cell 
proliferation. Consequently, it promotes a higher cell survival and 
genetic instability that contributes to malignant transformations(14).
Main tumor suppressor genes related to the 
pathogenesis and prognosis of DLBCL
p53 Gene
The p53 gene is located on chromosome 17, encoding a 
nuclear phosphoprotein p53. This protein acts by regulating 
the DNA transcription, cell proliferation and apoptosis(28). 
Sixty percent of malignant human tumors and 30% of B-cell 
lymphomas present the p53 mutation. Most of them occur in 
exons 5 and 9 and affect their function in the control of the 
DNA repair. Patients with absent or mutated p53 present more 
aggressive disease and worse prognosis(31). Some studies have 
suggested that p53 may be inactivated by the BCL6 gene during 
the genesis of lymphoma(14).
MYC Gene
MYC gene mutations may occur in regions of exons and 
introns(14). Recombination of the MYC gene with other genes can 
be found in 2% to 16% of DLBCL cases, especially in extranodal 
lymphomas. It is associated with lower complete remission and 
worse overall survival rates(12).
Main transcription factors in the pathogenesis and 
prognosis of DLBCL
The differentiation and proliferation of B-cells are controlled 
by transcription factors (32). Two of these factors are the OCT-1 
and OCT-2 proteins that belong to the POU family and are linked 
to genes involved in B-cell regulation(33).
The OCT-2 protein is little expressed in pre-B-cells, T-cells, 
myelomonocytic and epithelial cells. However, it is strongly 
expressed in mature B-cells. On the other hand, the OCT-1 
protein is highly expressed in pre-B-cells, suggesting that it may 
be involved in the early phase of B-cell development(33).
Recent studies have demonstrated, through the RNA 
interference technique, that OCT factors influence the survival of 
cells in lymphomas with the t(14; 18). A positive correlation was 
found between OCT, BOB1 and BCL2 expressions. OCT-2 activates 
the promoter of the BCL2 gene and is involved in the malignant 
transformation in B lymphomas. The low expressions of OCT-1, 
OCT-2 and BOB1 are inversely proportional to apoptosis(34).
Conclusions
DLBCL is the most common subtype of NHL and only 40 to 
50% of all adult patients are cured. Knowledge of the malignant 
cell biology has promoted an increase in the overall survival rate. 
However, this knowledge is incipient and many other studies of the 
gene expression of malignant cells and the tumor microenvironment 
are necessary. The advance in molecular biology techniques has 
been essential and its continuous improvement is fundamental to 
achieve maximum understanding of the biology. The final goal is to 
translate the knowledge of the biology of DLBCL into new options 
of therapy to try to improve patient survival.
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